コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the majority of cases reporting success with intravenous immunoglobulin.
2 reduction of immunosuppression, and frequent intravenous immunoglobulin.
3 o 7 days after completion of the infusion of intravenous immunoglobulin.
4 eroids in addition to plasma exchange and/or intravenous immunoglobulin.
5 Of those treated, 99% were treated with intravenous immunoglobulin.
6 asculitis that is treated with high doses of intravenous immunoglobulin.
7 rly axonal involvement, and poor response to intravenous immunoglobulin.
8 h groups received dopamine or dobutamine and intravenous immunoglobulin.
9 noadsorption, plasma exchange, and high-dose intravenous immunoglobulin.
10 ndomly assigned: 38 to eltrombopag and 36 to intravenous immunoglobulin.
11 rs for the purpose of developing hyperimmune intravenous immunoglobulin.
12 cal agents such as infliximab, rituximab and intravenous immunoglobulin.
13 erioperative eltrombopag was non-inferior to intravenous immunoglobulin.
14 rm was searched in combination with the term intravenous immunoglobulin.
15 imus, pimecrolimus, and imiquimod as well as intravenous immunoglobulin.
16 s of natural human IgG antibodies present in intravenous immunoglobulin.
17 id not respond to treatment with steroids or intravenous immunoglobulin.
18 inating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.
19 nd ecchymoses, and recovered after receiving intravenous immunoglobulin.
20 idofovir, leflunomide, fluoroquinolones, and intravenous immunoglobulins.
21 were observed for other therapies, including intravenous immunoglobulins.
22 ays preoperatively to postoperative day 7 or intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days befor
27 opag and 22 (61%) of 36 patients assigned to intravenous immunoglobulin (absolute risk difference 17.
30 not respond to steroids, plasmapheresis, and intravenous immunoglobulin after his third kidney transp
31 ications (fluorinated glucocorticoids and/or intravenous immunoglobulin) after enrollment but prior t
33 osal bleeding at diagnosis or treatment with intravenous immunoglobulin alone developed chronic ITP l
34 is regimen, the next step is the addition of intravenous immunoglobulin although this is not supporte
35 rugs, including biologic therapy, as well as intravenous immunoglobulin, although results have been m
36 nduced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylax
37 addition of infliximab to standard therapy (intravenous immunoglobulin and aspirin) in acute Kawasak
39 ously published trials evaluating the use of intravenous immunoglobulin and colony-stimulating factor
42 nd address the role of fluorinated steroids, intravenous immunoglobulin and hydroxychloroquine for pr
43 re incubated on glass coverslips coated with intravenous immunoglobulin and inactive complement compo
48 estigated the effect of desensitization with intravenous immunoglobulin and rituximab on the antibody
49 f four plasmapheresis treatments followed by intravenous immunoglobulin and splenectomy at the time o
50 ition was not treated with plasmapheresis or intravenous immunoglobulin and was not associated with p
51 Treatment with glucocorticoids-less so with intravenous immunoglobulins and plasma exchange-was asso
52 For 2 years, the patient was treated with intravenous immunoglobulins and steroids, with partial i
53 ral arm of the immune system by using either intravenous immunoglobulins and/or immunoadsorption will
54 ve therapy (azathioprine or methotrexate and intravenous immunoglobulin) and had normalization of str
55 ith antitumor necrosis factor agents, pooled intravenous immunoglobulin, and anti-B-cell therapies su
56 (using plasmapheresis followed by 100 mg/kg intravenous immunoglobulin, and anti-CD20 antibody), and
57 nts, and was reversible with plasmapheresis, intravenous immunoglobulin, and increasing immunosuppres
62 ination of anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange; there i
63 immunomodulatory agents including steroids, intravenous immunoglobulin, and plasmapheresis have show
64 yte antigen antibodies using plasmapheresis, intravenous immunoglobulin, and rituximab has been repor
65 ived previous treatment with plasmapheresis, intravenous immunoglobulin, and rituximab that was ineff
68 ing plasmapheresis preconditioning, low-dose intravenous immunoglobulin, and standard maintenance imm
69 ith an aggressive onset, a refractoriness to intravenous immunoglobulin, and tremor of possible cereb
70 pies including corticosteroids, splenectomy, intravenous immunoglobulin, and various cytotoxic or imm
71 e impossible for mycophenolate, montelukast, intravenous immunoglobulins, and systemic glucocorticost
72 responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at s
73 patients received intravenous steroids; 43, intravenous immunoglobulin; and 13, plasma exchange; or
74 of the underling inflammatory condition with intravenous immunoglobulin, anti TNF agents, thalidomide
75 been suggested, including administration of intravenous immunoglobulin, apheresis, and combination t
76 manage, but antimalarials, methotrexate, and intravenous immunoglobulin are effective in small, often
78 ated the efficacy of subcutaneous as well as intravenous immunoglobulin as maintenance therapy, and n
81 ivalent efficacy of both plasma exchange and intravenous immunoglobulin, but not corticosteroids, in
82 tients improve with GABA-enhancing drugs and intravenous immunoglobulin, but some respond poorly and
83 trate that the anti-inflammatory activity of intravenous immunoglobulin can be recapitulated by the t
84 econdary causes, we treated the patient with intravenous immunoglobulin, considering primary neuromyo
85 g therapies, including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresi
86 ed nonimmune were offered MMR vaccination or intravenous immunoglobulin depending on their transplant
87 rticotropin hormone, corticosteroids, and/or intravenous immunoglobulin, develop long-term neurologic
90 ethylprednisolone for 5 days, 0.4 mg/kg/d of intravenous immunoglobulin for 5 days, and 2 doses of ri
91 rdiography is a criterion for treatment with intravenous immunoglobulin for incomplete Kawasaki disea
92 Eltrombopag is an effective alternative to intravenous immunoglobulin for perioperative treatment o
95 by individual human sera or by pooled human, intravenous immunoglobulin G (IVIG) were dispersed over
96 osomes (n=2) or commercially available human intravenous immunoglobulin G depleted of anti-Gal Ab (n=
97 reductions in immunosuppressive medication, intravenous immunoglobulin, ganciclovir, and rituximab.
98 eltrombopag group and 20 (63%) of 32 in the intravenous immunoglobulin group (absolute risk differen
99 Five serious adverse events occurred in the intravenous immunoglobulin group (atrial fibrillation, p
100 Despite the use of plasma exchanges and intravenous immunoglobulins, Guillain-Barre syndrome (GB
102 usion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an e
103 xisting therapeutics such as the delivery of intravenous immunoglobulin have led to interest in devel
104 lescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical b
105 esponses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized.
106 a mouse model of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and
107 osuppression and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavi
108 investigate the effect of Thymoglobulin and intravenous immunoglobulin (i.v.IG) therapy on the clini
110 unodeficiency (PI) is equally efficacious to intravenous immunoglobulin (IGIV), induces fewer systemi
111 -term follow-up data received immunotherapy (intravenous immunoglobulin in 10 and corticosteroids and
114 ramer acetate in primary progressive MS, and intravenous immunoglobulin in secondary progressive MS).
115 thymoglobulin induction, plasmapheresis, and intravenous immunoglobulin in the highest risk groups.
116 echanisms of action, efficacy, and safety of intravenous immunoglobulins in rheumatic diseases demons
118 ressive protocol consisted of plasmapheresis/intravenous immunoglobulin infusion before LDLT followed
120 vel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted cort
123 ry aneurysms; this risk is reduced 5-fold if intravenous immunoglobulin is administered within 10 day
125 bocytopenic bleeding in the third trimester, intravenous immunoglobulin is an appropriate first-line
126 are at risk of bleeding during surgery, and intravenous immunoglobulin is commonly used to increase
131 phosphamide combined with plasmapheresis and intravenous immunoglobulins is an option for patients wi
132 infants born to mothers following antenatal intravenous immunoglobulin (IVIG) +/- prednisone therapy
133 two groups, namely 30 who were treated with intravenous immunoglobulin (IVIG) and 10 who achieved re
135 rtiary centers compared the effectiveness of intravenous immunoglobulin (IVIg) and corticosteroids in
136 ctiveness of desensitization using high-dose intravenous immunoglobulin (IVIG) and rituximab to impro
137 e than 5 years to investigate the effects of intravenous immunoglobulin (IVIG) and rituximab treatmen
139 inations of various antimicrobial agents and intravenous immunoglobulin (IVIG) as well as hyperbaric
140 anaphylactoid reactions on administration of intravenous immunoglobulin (IVIg) associated with the pr
142 of administering during pregnancy high-dose intravenous immunoglobulin (IVIG) derived from pooled se
144 neglobulin (anti-D) and 6 of 8 responding to intravenous immunoglobulin (IVIG) did not have correspon
147 trial showed short and long-term efficacy of intravenous immunoglobulin (IVIG) for the treatment of C
148 sma collected pre- and postadministration of intravenous immunoglobulin (IVIG) from patients with gro
152 evels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, doubl
153 were conducted to investigate the effects of intravenous immunoglobulin (IVIG) in a rat model of immu
154 nized paradigm for the therapeutic action of intravenous immunoglobulin (IVIG) in immune thrombocytop
155 espite the beneficial therapeutic effects of intravenous immunoglobulin (IVIg) in inflammatory diseas
156 ebo-controlled trial to evaluate efficacy of intravenous immunoglobulin (IVIG) in reducing seizure fr
169 ith rabbit antithymocyte globulin (RATG) and intravenous immunoglobulin (IVIG) may allow successful t
176 althy people and routinely in pharmaceutical intravenous immunoglobulin (IVIG) purified from serum po
178 IgG-Fc receptor gene FcgammaRIIB influences intravenous immunoglobulin (IVIG) response in Kawasaki d
179 cytic cells, and a commercial preparation of intravenous immunoglobulin (IVIG) served as the source o
181 rpose of this study was to determine whether intravenous immunoglobulin (IVIG) therapy could prevent
187 antibody-deficient patients before and after intravenous immunoglobulin (IVIG) therapy, 5 recently tr
190 acterized PANDAS, both at baseline and after intravenous immunoglobulin (IVIG) treatment, and 23 matc
191 patient received one plasmapheresis (PP) and intravenous immunoglobulin (IVIg) treatment, anti-CD25,
192 ers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preve
193 provement on the disability grade scale with intravenous immunoglobulin (IVIg) was very similar to th
194 ith AHR treated with plasmapheresis (PP) and intravenous immunoglobulin (IVIG) with allograft surviva
198 olysis, and cumulative doses of steroids and intravenous immunoglobulin (IVIG), and ameliorates neuro
200 ents, such as glucocorticoids, vitamin D, or intravenous immunoglobulin (IVIG), are discussed, as the
201 ioperative treatment with plasmapheresis and intravenous immunoglobulin (IVIG), combined with a tacro
202 Other options include plasmapheresis and intravenous immunoglobulin (IVIg), coupled with cytotoxi
203 The US Food and Drug Administration approved intravenous immunoglobulin (IVIg), extracted from the pl
204 tandard practice, aerosolized ribavirin plus intravenous immunoglobulin (IVIG), is extremely expensiv
206 otrexate antibody (AMI)-coated liposomes and intravenous immunoglobulin (IVIG)-coated liposomes (15,
207 of CD177 transcript in acute KD, and in the intravenous immunoglobulin (IVIG)-resistant group compar
220 is of HBV serology in 16 patients commencing intravenous immunoglobulin (IVIG); and pre- and post-inf
221 n G (IgG) purified from pooled human plasma [intravenous immunoglobulin (IVIG)] confer anti-inflammat
225 orticosteroids, dupilumab, interferon-gamma, intravenous immunoglobulins (IVIG), mepolizumab, methotr
226 have shown that pooled human gammaglobulin (intravenous immunoglobulin [IVIG]) inhibits the mixed ly
227 ingent selection with pooled human antisera (intravenous immunoglobulin [IVIG]) then led to the selec
228 enters (29 receiving plasmapheresis/low-dose intravenous immunoglobulin [IVIg]; 9 patients receiving
232 the immune system of the neonate, including: intravenous immunoglobulins, myeloid hematopoietic growt
233 Treatment included corticosteroids (n = 7), intravenous immunoglobulin (n = 3), and plasma exchange
234 rapy consisted of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasma
235 smapheresis, colchicine, hydroxychloroquine, intravenous immunoglobulin, nonsteroidal anti-inflammato
236 y [cPRA], 34%-99%), desensitization included intravenous immunoglobulin on days 0 and 30 and a single
238 s, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10
239 consensus was reached concerning the use of intravenous immunoglobulin or corticosteroids as first-l
240 immunoglobulin in 10 and corticosteroids and intravenous immunoglobulin or other immunosuppressors in
241 or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 mon
243 within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 w
244 Severe cases and acute worsening require intravenous immunoglobulin or plasmapheresis before oral
247 with a combination of methylprednisolone and intravenous immunoglobulin (OR 2.67, 95% CI 1.44-4.96).
249 esection and immunotherapy (corticosteroids, intravenous immunoglobulin, or plasma exchange) respond
250 Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunos
251 on protocol starting at day 0 with high-dose intravenous immunoglobulin, plasma exchanges, and eventu
252 included first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line
253 nvolve antibody suppression and removal with intravenous immunoglobulin, plasmapheresis, and antibody
254 blood group incompatible transplant using an intravenous immunoglobulin/plasmapheresis preconditionin
255 more than four pretransplant plasmapheresis/intravenous immunoglobulin (PP/IVIg) had a greater likel
263 stent low B-lymphocyte count and remained on intravenous immunoglobulin replacement, 2 had second HCT
266 underwent treatment with corticosteroids and intravenous immunoglobulin, resulting in clinical improv
272 to a third of KD patients fail to respond to intravenous immunoglobulin, the standard therapy, and al
275 e antibodies must be in some doubt, although intravenous immunoglobulin therapy has been shown to be
276 anti-inflammatory properties associated with intravenous immunoglobulin therapy require the sialic ac
277 and a lack of response to corticosteroid and intravenous immunoglobulin therapy, a 3-day course of pl
278 itioning regimen using plasmapheresis and/or intravenous immunoglobulin therapy, but underlying mecha
281 ibodies were affinity purified by passage of intravenous immunoglobulin through purified, type-specif
283 d with thymocytes from ITP mice treated with intravenous immunoglobulin, thymocytes from untreated IT
284 treated with corticosteroids in addition to intravenous immunoglobulin to improve their outcomes.
289 h definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible.
290 otection, as well as the limited efficacy of intravenous immunoglobulin treatments against human dise
291 nced by immunoglobulin production, decreased intravenous immunoglobulin use, and antibody response af
292 d first-line immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and
293 ble regimes of steroids, plasma exchange and intravenous immunoglobulin were associated with variable
294 though a consensus agreed that biologics and intravenous immunoglobulin were considered appropriate i
297 ki disease (KD) and 5% of those treated with intravenous immunoglobulin will develop coronary artery
299 e patients were treated with steroids and/or intravenous immunoglobulin, with variable positive respo